The company hopes to benefit citizens and shed new light on the treatment of cancer. Pfizer Taiwan and the National Health Research Institutes (NHRI), along with two other partnering companies, recently signed a precision medicine cooperation alliance agreement, officially launching a joint initiative to develop precision cancer treatments in Taiwan. The agreement commits all parties…

Finding effective solutions to the world’s health issues requires novel, holistic approaches and collaborative ingenuity. Healthcare companies must therefore increasingly shift their focus to the research and development of medical technologies, biopharmaceuticals, and innovative therapies to treat conditions and diseases that are difficult or nearly impossible to tackle using traditional medicines. Such a reality is…

For GlaxoSmithKline Taiwan (GSK) General Manager Mick Stanley, a company is only as successful and progressive as the people behind it. He cites the multinational pharmaceutical firm’s ability to balance performance with pursuing solutions that positivity impact patients and public health as one of the main reasons he’s stayed with them for the last 20…

An annual report lists Taiwan-related trade issues being followed in Washington. Early each year, the Office of the U.S. Trade Representative (USTR) releases a country-by-country Report on Foreign Trade Barriers. The nine-page Taiwan section for 2020 provides a concise statement of the main areas of U.S.-government concern regarding elements of the bilateral trade relationship. Taiwan’s…

AmCham’s Pharmaceutical Committee has suggestions. Year after year, a key concern of the major pharmaceutical companies operating in Taiwan is the ease with which new drugs and new indications (meaning new applications for existing treatments) can enter the market. Given Taiwan’s single-payer universal healthcare system, much depends on whether the National Health Insurance Administration (NHIA)…

Taiwan’s establishment of a well-formulated Patent Linkage system for pharmaceuticals is a landmark development not only for the drug industry but for this country’s intellectual property rights protection in general. In addition, it boosts Taiwan’s status in the global trading community and improves its prospects for eventually concluding bilateral or multilateral free trade agreements with…

It’s imperative to devote more resources to infectious-disease control, leading to the development of new antibiotics. In 2015, the U.S. White House launched a national action plan against antimicrobial resistance (AMR), also commonly known as antibiotic resistance. In 2017, the World Health Organization (WHO) announced the 12 types of highly resistant bacteria that pose the…